The VHL gene is epigenetically inactivated in pheochromocytomas and abdominal paragangliomas

Epigenetics

Volumn 8, Issue 12, 2013, Pages 1347-1354

  Andreasson, Adam ^a   Kiss, Nimrod B ^a   Caramuta, Stefano ^a   Sulaiman, Luqman ^a   Svahn, Fredrika ^a   Bäckdahl, Martin ^a,b   Höög, Anders ^a   Christofer Juhlin, C ^a   Larsson, Catharina ^a  

^a KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

^b KAROLINSKA INSTITUTE   (Sweden)

Author keywords

DNA promoter methylation; Gene expression; Paraganglioma; Pheochromocytoma; Pyrosequencing; qRT PCR; VHL

Indexed keywords

CATECHOLAMINE; SUCCINATE DEHYDROGENASE;

ARTICLE; CONTROLLED STUDY; EPIGENETICS; FOLLOW UP; GENE; GENE EXPRESSION; GENETIC PREDISPOSITION; HUMAN; HUMAN TISSUE; NUCLEOTIDE SEQUENCE; PARAGANGLIOMA; PHEOCHROMOCYTOMA; PYROSEQUENCING; REAL TIME POLYMERASE CHAIN REACTION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SEQUENCE ANALYSIS; TRANSLATION INITIATION; VHL GENE;

DNA PROMOTER METHYLATION; GENE EXPRESSION; PARAGANGLIOMA; PHEOCHROMOCYTOMA; PYROSEQUENCING; QRT-PCR; VHL;

ABDOMINAL NEOPLASMS; ADRENAL GLAND NEOPLASMS; BASE SEQUENCE; CASE-CONTROL STUDIES; DNA METHYLATION; DOWN-REGULATION; EPIGENESIS, GENETIC; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; MOLECULAR SEQUENCE DATA; PARAGANGLIOMA; PHEOCHROMOCYTOMA; PROMOTER REGIONS, GENETIC; RNA, MESSENGER; VON HIPPEL-LINDAU TUMOR SUPPRESSOR PROTEIN;

EID: 84888794927     PISSN: 15592294     EISSN: 15592308     Source Type: Journal    
DOI: 10.4161/epi.26686     Document Type: Article

References (28)

1. DeLellis R. Pathology and genetics of tumours of endocrine organs. Lyon: IARC Press; 2004. 136-166 p.
2. Bravo EL, Gifford RW Jr. Current concepts. Pheochromocytoma: diagnosis, localization and management. N Engl J Med 1984; 311:1298-303; PMID:6149463; http://dx.doi.org/10.1056/ NEJM198411153112007
3. Sutton MG, Sheps SG, Lie JT. Prevalence of clinically unsuspected pheochromocytoma. Review of a 50-year autopsy series. Mayo Clin Proc 1981; 56:354-60; PMID:6453259
4. Neumann HPH, Bausch B, McWhinney SR, Bender BU, Gimm O, Franke G, Schipper J, Klisch J, Altehoefer C, Zerres K, et al.; Freiburg-Warsaw-Columbus Pheochromocytoma Study Group. Germline mutations in nonsyndromic pheochromocytoma. N Engl J Med 2002; 346:1459-66; PMID:12000816; http://dx.doi.org/10.1056/NEJMoa020152
5. Jafri M, Maher ER. The genetics of phaeochromocytoma: using clinical features to guide genetic testing. Eur J Endocrinol 2012; 166:151-8; PMID:21896620; http://dx.doi.org/10.1530/EJE-11-0497
6. Yeh I-T, Lenci RE, Qin Y, Buddavarapu K, Ligon AH, Leteurtre E, Do Cao C, Cardot-Bauters C, Pigny P, Dahia PLM. A germline mutation of the KIF1B beta gene on 1p36 in a family with neural and nonneural tumors. Hum Genet 2008; 124:279-85; PMID:18726616; http://dx.doi.org/10.1007/ s00439-008-0553-1
7. Bayley J-P, Kunst HPM, Cascon A, Sampietro ML, Gaal J, Korpershoek E, Hinojar-Gutierrez A, Timmers HJLM, Hoefsloot LH, Hermsen MA, et al. SDHAF2 mutations in familial and sporadic paraganglioma and phaeochromocytoma. Lancet Oncol 2010; 11:366-72; PMID:20071235; http://dx.doi. org/10.1016/S1470-2045(10)70007-3
8. Astuti D, Ricketts CJ, Chowdhury R, McDonough MA, Gentle D, Kirby G, Schlisio S, Kenchappa RS, Carter BD, Kaelin WG Jr., et al. Mutation analysis of HIF prolyl hydroxylases (PHD/EGLN) in individuals with features of phaeochromocytoma and renal cell carcinoma susceptibility. Endocr Relat Cancer 2011; 18:73-83; PMID:20959442; http://dx.doi. org/10.1677/ERC-10-0113
9. Comino-Méndez I, de Cubas AA, Bernal C, Álvarez-Escolá C, Sánchez-Malo C, Ramírez-Tortosa CL, Pedrinaci S, Rapizzi E, Ercolino T, Bernini G, et al. Tumoral EPAS1 (HIF2A) mutations explain sporadic pheochromocytoma and paraganglioma in the absence of erythrocytosis. Hum Mol Genet 2013; 22:2169-76; PMID:23418310; http://dx.doi. org/10.1093/hmg/ddt069
10. Burnichon N, Buffet A, Parfait B, Letouzé E, Laurendeau I, Loriot C, Pasmant E, Abermil N, Valeyrie-Allanore L, Bertherat J, et al. Somatic NF1 inactivation is a frequent event in sporadic pheochromocytoma. Hum Mol Genet 2012; 21:5397-405; PMID:22962301; http://dx.doi.org/10.1093/hmg/ dds374
11. Welander J, Larsson C, Bäckdahl M, Hareni N, Sivlér T, Brauckhoff M, Söderkvist P, Gimm O. Integrative genomics reveals frequent somatic NF1 mutations in sporadic pheochromocytomas. Hum Mol Genet 2012; 21:5406-16; PMID:23010473; http://dx.doi. org/10.1093/hmg/dds402
12. Geli J, Kiss N, Karimi M, Lee J-J, Bäckdahl M, Ekström TJ, Larsson C. Global and regional CpG methylation in pheochromocytomas and abdominal paragangliomas: association to malignant behavior. Clin Cancer Res 2008; 14:2551-9; PMID:18451216; http://dx.doi.org/10.1158/1078-0432.CCR-07-1867
13. Kiss NB, Muth A, Andreasson A, Juhlin CC, Geli J, Bäckdahl M, Höög A, Wängberg B, Nilsson O, Ahlman H, et al. Acquired hypermethylation of the P16INK4A promoter in abdominal paraganglioma: relation to adverse tumor phenotype and predisposing mutation. Endocr Relat Cancer 2013; 20:65-78; PMID:23154831; http://dx.doi.org/10.1530/ ERC-12-0267
14. Letouzé E, Martinelli C, Loriot C, Burnichon N, Abermil N, Ottolenghi C, Janin M, Menara M, Nguyen AT, Benit P, et al. SDH mutations establish a hypermethylator phenotype in paraganglioma. Cancer Cell 2013; 23:739-52; PMID:23707781; http://dx.doi.org/10.1016/j.ccr.2013.04.018
15. Cascon A, Ruiz-Llorente S, Fraga MF, Leton R, Telleria D, Sastre J, Diez JJ, Martinez Diaz-Guerra G, Diaz Perez JA, Benitez J, et al. Genetic and epigenetic profile of sporadic pheochromocytomas. J Med Genet 2004; 41:e30; PMID:14985401; http:// dx.doi.org/10.1136/jmg.2003.012658
16. Dammann R, Schagdarsurengin U, Seidel C, Trümpler C, Hoang-Vu C, Gimm O, Dralle H, Pfeifer GP, Brauckhoff M. Frequent promoter methylation of tumor-related genes in sporadic and men2-associated pheochromocytomas. Exp Clin Endocrinol Diabetes 2005; 113:1-7; PMID:15662588; http://dx.doi. org/10.1055/s-2004-830522
17. Feinberg AP, Vogelstein B. Hypomethylation distinguishes genes of some human cancers from their normal counterparts. Nature 1983; 301:89-92; PMID:6185846; http://dx.doi. org/10.1038/301089a0
18. Valera VA, Walter BA, Linehan WM, Merino MJ. Regulatory Effects of microRNA-92 (miR-92) on VHL Gene Expression and the Hypoxic Activation of miR-210 in Clear Cell Renal Cell Carcinoma. J Cancer 2011; 2:515-26; PMID:22043236; http:// dx.doi.org/10.7150/jca.2.515
19. Moore LE, Nickerson ML, Brennan P, Toro JR, Jaeger E, Rinsky J, Han SS, Zaridze D, Matveev V, Janout V, et al. Von Hippel-Lindau (VHL) inactivation in sporadic clear cell renal cancer: associations with germline VHL polymorphisms and etiologic risk factors. PLoS Genet 2011; 7:e1002312; PMID:22022277; http://dx.doi.org/10.1371/journal.pgen.1002312
20. Elkahloun AG, Powers JF, Nyska A, Eisenhofer G, Tischler AS. Gene expression profiling of rat pheochromocytoma. Ann N Y Acad Sci 2006; 1073:290-9; PMID:17102098; http://dx.doi.org/10.1196/ annals.1353.033
21. Waldmann J, Fendrich V, Holler J, Buchholz M, Heinmöller E, Langer P, Ramaswamy A, Samans B, Walz MK, Rothmund M, et al. Microarray analysis reveals differential expression of benign and malignant pheochromocytoma. Endocr Relat Cancer 2010; 17:743-56; PMID:20562231; http://dx.doi. org/10.1677/ERC-09-0118
22. Eisenhofer G, Huynh T-T, Pacak K, Brouwers FM, Walther MM, Linehan WM, Munson PJ, Mannelli M, Goldstein DS, Elkahloun AG. Distinct gene expression profiles in norepinephrine-and epinephrine-producing hereditary and sporadic pheochromocytomas: activation of hypoxia-driven angiogenic pathways in von Hippel-Lindau syndrome. Endocr Relat Cancer 2004; 11:897-911; PMID:15613462; http://dx.doi.org/10.1677/erc.1.00838
23. Dahia PLM, Ross KN, Wright ME, Hayashida CY, Santagata S, Barontini M, Kung AL, Sanso G, Powers JF, Tischler AS, et al. A HIF1alpha regulatory loop links hypoxia and mitochondrial signals in pheochromocytomas. PLoS Genet 2005; 1:72-80; PMID:16103922; http://dx.doi.org/10.1371/journal. pgen.0010008
24. Thouënnon E, Elkahloun AG, Guillemot J, Gimenez-Roqueplo A-P, Bertherat J, Pierre A, Ghzili H, Grumolato L, Muresan M, Klein M, et al. Identification of potential gene markers and insights into the pathophysiology of pheochromocytoma malignancy. J Clin Endocrinol Metab 2007; 92:4865-72; PMID:17878247; http://dx.doi. org/10.1210/jc.2007-1253
25. Lack EE. Tumors of the adrenal glands and extraadrenal paraganglia. Washington DC, USA: American Registry of Pathology in collaboration with the Armed Forces Institute of Pathology. 2007. 274-276 p.
26. Sulaiman L, Juhlin CC, Nilsson I-L, Fotouhi O, Larsson C, Hashemi J. Global and gene-specific promoter methylation analysis in primary hyperparathyroidism. Epigenetics 2013; 8:646-55; http://dx.doi. org/10.4161/epi.24823; PMID:23764768
27. Juhlin CC, Kiss NB, Villablanca A, Haglund F, Nordenström J, Höög A, Larsson C. Frequent promoter hypermethylation of the APC and RASSF1A tumour suppressors in parathyroid tumours. PLoS One 2010; 5:e9472; PMID:20208994; http://dx.doi. org/10.1371/journal.pone.0009472
28. Bustin SA, Benes V, Garson JA, Hellemans J, Huggett J, Kubista M, Mueller R, Nolan T, Pfaffl MW, Shipley GL, et al. The MIQE guidelines: minimum information for publication of quantitative realtime PCR experiments. Clin Chem 2009; 55:611-22; PMID:19246619; http://dx.doi.org/10.1373/ clinchem.2008.112797